record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
ONC201 phase I dose escalation/expansion pediatric DMG trial, Neuro-Oncology
authors
reviewer:will-blair
ONC201 phase I pediatric DMG/DIPG trial established pediatric-weight-scaled dosing (adult RP2D 625 mg scaled to body weight) with recommended phase II dose determination—adult oncology regimens require de novo pediatric pharmacokinetic/pharmacodynamic validation.
vs_e69aeb00b1b9ef83 · manual_curation
outgoing
vf_4171b4670921b306IDH1-mutant rarity in pediatric HGG (5-10% vs 35% adult) requires pediatric-specific precision enrollment, not adult extrapolation
incoming
No incoming links.
events
vev_07a700809e50d72cfinding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_c9c2f49203860ed5finding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.